News | Proton Therapy | February 16, 2016

Mevion S250 Proton Therapy System Comes to Nation's Capital

Mevion proton accelerator arrives at Medstar Georgetown; one of multiple Mevion sites to achieve installation milestones

Mevion S250, proton therapy, Medstar Georgetown installation, Washington D.C.

February 16, 2016 – A superconducting synchrocyclotron proton accelerator was delivered Valentine’s Day weekend to MedStar Georgetown University Hospital. The accelerator, which will become the core of the hospital’s Mevion S250 proton therapy system, was developed and manufactured in the United States and is one of only eight in existence.

When installation is complete, cancer patients in the Washington, D.C. area will gain access to proton therapy — an advanced form of radiation treatment that targets tumors precisely, while sparing much of the surrounding healthy tissue. Because of its accuracy, proton therapy is ideal for treating pediatric patients, as well as adults with cancers in or near sensitive locations, such as the heart, lungs, brain, eye or spinal cord.

Conventional proton therapy systems can cost over $200 million to construct and are typically the size of a football field. The Mevion S250 delivers proton therapy for up to 80 percent less cost and 90 percent less space. Mevion systems also require up to 75 percent fewer staff and use up to 90 percent less energy than other proton systems. Furthermore, Mevion says its proton systems have an industry leading ramp-up time, throughput capabilities and uptime.

Installation of the system at MedStar Georgetown will take approximately 10 months. The system will then undergo proton beam tuning to meet the precise clinical requirements for patient treatments. The first proton therapy patient is expected to be treated at MedStar Georgetown in early 2017.

The Washington, D.C. installation begins as Ackerman Cancer Center (ACC) in Jacksonville, Fla., breaks ground on the construction of a radiation vault for its second Mevion S250 Series system. ACC will be installing a Mevion S250i with Hyperscan pencil beam scanning technology.

The first system opened last April, and quickly achieved the fastest per-room ramp-up in the history of proton therapy. The installation is expected to be completed in 2017.

Meanwhile, the Mevion S250 under installation at the University of Florida (UF) Health Cancer Center – Orlando Health, in Orlando, Fla., has also achieved a major milestone. It has completed its rigorous acceptance testing and is now entering the clinical commissioning phase. Clinical commissioning is the final step before the first patient is treated.

During an intensive seven days of acceptance testing, the system in Orlando met or exceeded all specifications. Its operational control has been officially transitioned to the physics and radiation oncology proton teams at UF Health Cancer Center. It is expected to begin treating patients in a few months.

For more information: www.mevion.com

Related Content

Varian received FDA clearance for its Ethos therapy in February 2020. It is an adaptive intelligence solution that uses onboard AI in the treatment system to take the cone beam CT imaging on the system, compare it to the treatment plan and deliver an entire adaptive treatment plan in a typical 15-minute treatment time slot, from patient setup through treatment delivery.

Varian received FDA clearance for its Ethos therapy in February 2020, shown here displayed for the first time at ASTRO 2019. It is an adaptive intelligence solution that uses onboard AI in the treatment system to take the cone beam CT imaging on the system, compare it to the treatment plan and deliver an entire adaptive treatment plan in a typical 15-minute treatment time slot, from patient setup through treatment delivery.

Feature | Treatment Planning | April 03, 2020 | Dave Fornell, Editor
The traditional treatment planning process takes days to create an optimized radiation therapy delivery plan, but new
Women are more likely to be cured of cancer by radiotherapy but the side effects are worse.

Women are more likely to be cured of cancer by radiotherapy but the side effects are worse. Image by Mark Kostich

News | Radiation Therapy | March 30, 2020
March 30, 2020 — Women undergoing radiotherapy for
A new framework from an international team of experts aims to help protect patients and providers, and conserve protective equipment for frontline healthcare workers #COVID19 #Coronavirus #2019nCoV #Wuhanvirus #SARScov2
News | Prostate Cancer | March 30, 2020
March 30, 2020 — In the wake of the COVID-19 pan
Accuray Incorporated announced that Mercy Hospital St. Louis continues to demonstrate its commitment to improving patient outcomes with the installation of the first CyberKnife M6 System in Missouri at their state-of-the-art David C. Pratt Cancer Center
News | Stereotactic Body Radiation Therapy (SBRT) | February 27, 2020
February 27, 2020 — Accuray Incorporated announced that Mercy
Arizona State University researchers (in collaboration with Banner MD Anderson Cancer Center) have discovered a biocompatible cost-effective hydrogel that can be used to monitor therapeutic doses of ionizing radiation by becoming more pink with increasing radiation exposure

Arizona State University researchers (in collaboration with Banner MD Anderson Cancer Center) have discovered a biocompatible cost-effective hydrogel that can be used to monitor therapeutic doses of ionizing radiation by becoming more pink with increasing radiation exposure. This picture shows a circle of hydrogel that was irradiated on the left half, which is slightly pink; whereas the right half of the gel is not irradiated and remains colorless.

News | Radiation Therapy | February 18, 2020
February 18, 2020 — More than half of all cancer patients undergo radiation therapy and the dose is critical.
Varian announced it has received FDA 510(k) clearance for its Ethos therapy, an Adaptive Intelligence solution. Ethos therapy is an artificial intelligence (AI)-driven holistic solution that provides an opportunity to transform cancer care.
News | Image Guided Radiation Therapy (IGRT) | February 11, 2020
February 11, 2020 — Varian announced it has received FDA 510(k) c
The radiation therapy market is projected to grow in through 2026

Image courtesy of Accuray

News | Proton Therapy | February 10, 2020
February 10, 2020 — Amid technological advancement, and notable research and development activities, the global ...
Accuray TomoTherapy total body irradiation
News | Radiation Therapy | February 07, 2020
February 7, 2020 — Accuray Incorporated announced that two new studies demonstrate the benefits of the ...
The luminescent oxygen probe PtG4 is injected during the week of radiation treatment and localizes between the cells of the tumor as illustrated by microscopy

An oxygen map image recovered from a mouse undergoing radiation therapy. The luminescent oxygen probe PtG4 is injected during the week of radiation treatment and localizes between the cells of the tumor as illustrated by microscopy (red). Image courtesy of Brian Pogue, PhD

News | Radiation Therapy | February 03, 2020
February 3, 2020 — Oxygen in cancer tumors is known to be a major factor that helps radiation therapy be successful.